Klotho Neurosciences Inc (KLTO)
$0.5
Market is closed - opens 7 PM, 09 Oct 2024
Performance
- $0.47$0.52$0.50
5.95%
Downside
Day's Volatility :9.39%
Upside
3.66%
- $0.47$0.99$0.50
5.96%
Downside
52 Weeks Volatility :52.51%
Upside
49.49%
Returns
| Period | Klotho Neurosciences Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -45.44% | 0.0% |
6 Months | -95.46% | 0.0% |
1 Year | -95.32% | 0.0% |
3 Years | -94.95% | -20.8% |
Highlights
Market Capitalization | 17.6M |
Book Value | - $0.1 |
Earnings Per Share (EPS) | 0.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -23.57% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Klotho Neurosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Klotho Neurosciences Inc | -46.13% | -95.46% | -95.32% | -94.95% | -94.95% |
 Regeneron Pharmaceuticals, Inc. | -12.19% | 6.5% | 20.85% | 84.03% | 245.65% |
 Novo Nordisk A/s | -11.15% | -6.13% | 27.31% | 138.21% | 354.53% |
 Alnylam Pharmaceuticals, Inc. | 5.38% | 73.95% | 61.12% | 32.59% | 252.19% |
 Vertex Pharmaceuticals Incorporated | -2.58% | 13.46% | 29.21% | 155.56% | 172.0% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Klotho Neurosciences Inc | NA | NA | NA | 0.0 | 0.0 | -0.24 | NA | -0.1 |
Regeneron Pharmaceuticals, Inc. | 26.37 | 26.37 | 1.36 | 45.03 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.54 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Klotho Neurosciences Inc | NA | NA | -94.95% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $109.8B | 245.65% | 26.37 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 354.53% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.2B | 252.19% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $115.8B | 172.0% | 32.84 | -4.74% |
Insights on Klotho Neurosciences Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.1% return, outperforming this stock by 156.4%
Company Information
Organization | Klotho Neurosciences Inc |
Industry | Miscellaneous |
Discover More
Virios Therapeutics Inc
$0.50
-1.26%
Lg Qraft Ai-powered Us Large Cap Core Etf
$0.50
-1.26%
Spdr Ftse International Gove
$0.50
-1.26%
John Hancock Investors Closed Fund
$0.50
-1.26%
Proshares Ultra High Yield
$0.50
-1.26%
Lichen China Ltd
$0.50
-1.26%
Arbutus Biopharma Corporation
$0.50
-1.26%
Eaton Vance Enh Eqt Inc Ii
$0.50
-1.26%
Western Asset Diversified Income Fund
$0.50
-1.26%